Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset - HMS LINCS Database

Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

Filter results: >>>>

Cell	Small Molecule	Small Mol Concentration (uM)	Primary Target	Pathway	Mean Normalized Growth Rate Inhibition Value	Increased Fraction Dead
HCC1806	Neratinib	0.1	EGFR/HER2	RTK	0.7682	0.05014
HCC1806	Tivantinib	0.1	MET	RTK	0.9630	0.00521
HCC1806	Ceritinib	1.0	ALK	RTK	0.8590	0.02331
HCC1806	Neratinib	0.031623	EGFR/HER2	RTK	0.8990	0.02920
HCC1806	Tivantinib	0.001	MET	RTK	1.0293	0.00356
HCC1806	Tivantinib	0.031623	MET	RTK	1.0186	0.00130
HCC1806	Ceritinib	0.01	ALK	RTK	1.0487	0.00015
HCC1806	Ceritinib	0.31623	ALK	RTK	1.1237	-0.00775
HCC1806	Neratinib	0.00031623	EGFR/HER2	RTK	1.0684	0.00476
HCC1806	Neratinib	0.01	EGFR/HER2	RTK	0.9959	0.01677
HCC1806	Neratinib	1.0	EGFR/HER2	RTK	0.5513	0.07881
HCC1806	Neratinib	3.1623	EGFR/HER2	RTK	-0.0883	0.43583
HCC1806	Tivantinib	0.0031623	MET	RTK	0.9997	0.00401
HCC1806	Tivantinib	0.01	MET	RTK	1.0496	-0.00152
HCC1806	Ceritinib	0.001	ALK	RTK	1.0121	0.00605
HCC1806	Ceritinib	0.0031623	ALK	RTK	1.0658	-0.00214
HCC1806	Ceritinib	0.031623	ALK	RTK	1.0774	-0.00516
HCC1806	Ceritinib	0.1	ALK	RTK	1.0986	-0.00400
HCC1806	Ceritinib	3.1623	ALK	RTK	0.1763	0.12321
HCC1806	Ceritinib	10.0	ALK	RTK	-0.4060	0.58043
HCC1806	Neratinib	0.001	EGFR/HER2	RTK	1.0533	-0.00088
HCC1806	Neratinib	0.0031623	EGFR/HER2	RTK	1.0102	0.00509
HCC1806	Neratinib	0.31623	EGFR/HER2	RTK	0.7026	0.06151
HCC1806	Tivantinib	1.0	MET	RTK	-0.1778	0.49866
HCC1806	Tivantinib	0.31623	MET	RTK	0.3568	0.15622